Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J K Field

Showing results (141-150 of 145) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 145 results.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
ESMO Open|June 4, 2024
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-RA R Filippi, J Bar, C Chouaid, et al.
Thorax|December 10, 2015
UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screeningJ K Field, S W Duffy, D R Baldwin, et al.
The European Respiratory Journal|December 2, 2009
EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaborationJ K Field, T Liloglou, A Niaz, et al.
Nature Communications|August 22, 2019
Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoidsN Alcala, N Leblay, A A G Gabriel, et al.
Pageof 15

Showing results (141-150 of 145) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 145 results.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
ESMO Open|June 4, 2024
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-RA R Filippi, J Bar, C Chouaid, et al.
Thorax|December 10, 2015
UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screeningJ K Field, S W Duffy, D R Baldwin, et al.
The European Respiratory Journal|December 2, 2009
EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaborationJ K Field, T Liloglou, A Niaz, et al.
Nature Communications|August 22, 2019
Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoidsN Alcala, N Leblay, A A G Gabriel, et al.
Pageof 15